JAKARTA - Vice chairman of the House of Representatives for Economic and Financial Affairs Sufmi Dasco Ahmad volunteered for a phase II clinical trial of the Nusantara vaccine at the Army Central Hospital (RSPAD) Gatot Soebroto, Wednesday, April 15.
Dasco said that the process of taking blood samples for the sake of it went well. This blood sample will be processed for the next 7 days and put back into the body.
"Today I have taken a blood sample to be processed for 7 days as a vaccine nusantara. The process went well and I think it is not too long like the usual vaccination process," said Dasco at RSPAD, Jakarta, Wednesday, April 15.
Related to the blood sampling, Dasco explained, previously a medical examination has been conducted and there are some questions about the disease suffered.
He revealed the reasons for being willing to inject Vaksin Nusantara as an effort to support the production of vaccines in the country, especially the production of children of the nation.
"We know that vaccines from outside is also an easy entry into Indonesia, especially now that the vaccine embargo is carried out by vaccine-producing countries. Therefore we must support the existing vaccine," said the chairman of the Gerindra Party daily.
According to him, Nusantara vaccine will increase the wealth of domestic production vaccines so that it can help the government reduce the rate of COVID-19 in the country.
"I don't think it's worth debating because between one vaccine and another vaccine it's no problem," Dasco explained.
In line with Dasco, Vice Chairman of Commission IX of the House of Representatives Melkiades Laka Lena said, his arrival as a volunteer is a form of support for nusantara vaccine as a domestic product. Moreover, the depletion of vaccine stocks due to the embargo from the producer countries.
"If you choose to let this country can spin its economy, it can soon be healthy especially now vaccines are again difficult, India again embargo. We have less vaccines," Melki said.
In addition, the national vaccination target was also stalled due to a lack of vaccine supply. Moreover, the quality of vaccines from abroad efficacy is low so it is believed that the vaccine by former Minister of Health Terawan Agus Putranto can bring new hope.
"Our vaccination target is difficult to move because the vaccine is limited. The quality of the vaccine is also China itself says its Sinovac efficacy is low. That's what's got the product. Astrazeneca whose security is then the pros and cons abroad. So while there is production like this we support, in the country anyway," said the legislator from NTT.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
